MaltSci 麦伴科研

Appearance

Popular Reports / Cancer Research

This report is written by MaltSci based on the latest literature and research findings

How does radiation therapy work in cancer treatment? ​

Abstract ​

Radiation therapy (RT) has become a fundamental component of cancer management, employed in both curative and palliative settings. With more than half of cancer patients receiving radiation at some point during their treatment, understanding the mechanisms of action and optimizing its application is essential for improving therapeutic outcomes. RT primarily works by inducing DNA damage in cancer cells, leading to cell death; however, the development of radioresistance poses significant challenges to treatment efficacy. This review explores the cellular responses to radiation, the various types of radiation therapy, and recent technological advancements aimed at enhancing treatment precision. We discuss the intricate interplay between radiation therapy and the tumor microenvironment, emphasizing the role of immune modulation and cellular stress responses in influencing treatment effectiveness. Furthermore, we examine the potential of combining radiation therapy with chemotherapy and immunotherapy to maximize therapeutic benefits. Future directions in radiation therapy focus on personalized treatment approaches and the development of novel radiosensitizers. By synthesizing current research findings, this review aims to provide insights that may inform future strategies in radiation oncology, ultimately improving patient care and treatment outcomes.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Mechanisms of Radiation Therapy
    • 2.1 Cellular Response to Radiation
    • 2.2 DNA Damage and Repair Mechanisms
  • 3 Types of Radiation Therapy
    • 3.1 External Beam Radiation Therapy
    • 3.2 Brachytherapy
    • 3.3 Stereotactic Radiation Therapy
  • 4 Technological Advances in Radiation Therapy
    • 4.1 Intensity-Modulated Radiation Therapy (IMRT)
    • 4.2 Image-Guided Radiation Therapy (IGRT)
    • 4.3 Proton Therapy
  • 5 Combination with Other Treatment Modalities
    • 5.1 Radiation Therapy and Chemotherapy
    • 5.2 Radiation Therapy and Immunotherapy
  • 6 Future Directions in Radiation Therapy
    • 6.1 Personalized Radiation Therapy
    • 6.2 Research on Radio-sensitizers
  • 7 Summary

1 Introduction ​

Radiation therapy (RT) has established itself as a cornerstone in the management of cancer, utilized in both curative and palliative contexts. With over half of all cancer patients receiving radiation at some point during their treatment, understanding the underlying mechanisms and optimizing its application is critical for enhancing therapeutic outcomes [1]. RT employs high-energy radiation to induce DNA damage in cancer cells, ultimately leading to cell death. However, the effectiveness of this modality is often compromised by the development of radioresistance, wherein cancer cells adapt and survive despite exposure to radiation [2][3]. As such, exploring the biological effects of radiation, the types of therapies available, and advancements in technology is essential for improving patient care.

The significance of radiation therapy in oncology cannot be overstated. It serves not only as a primary treatment modality but also as an adjunct to surgery and chemotherapy, significantly improving local control and survival rates for various malignancies [4]. Despite its widespread use, challenges remain, particularly in understanding the molecular and cellular responses that contribute to resistance [5]. Recent research has illuminated the complex interplay between radiation and the tumor microenvironment, highlighting the role of immune modulation and cellular stress responses [6][7]. By delving into these aspects, we can develop strategies to enhance radiosensitivity and ultimately improve patient outcomes.

Current literature indicates a paradigm shift towards personalized radiation therapy, integrating advanced imaging and treatment techniques to tailor approaches to individual patient needs [8]. This review will explore several key areas: the mechanisms of radiation therapy, including cellular responses and DNA repair processes; the various types of radiation therapy, such as external beam radiation, brachytherapy, and stereotactic radiation; and the technological advancements that have emerged, including intensity-modulated radiation therapy (IMRT) and proton therapy [9]. Furthermore, we will examine the interplay between radiation therapy and other treatment modalities, such as chemotherapy and immunotherapy, emphasizing the importance of a multidisciplinary approach to cancer management [10].

In the following sections, we will discuss the cellular responses to radiation and the implications for treatment efficacy, particularly in the context of DNA damage and repair mechanisms [1][5]. We will categorize the types of radiation therapy and evaluate their respective benefits and limitations [8]. Technological innovations that enhance the precision of radiation delivery will also be reviewed, showcasing how these advancements contribute to better treatment outcomes [4]. Additionally, we will explore the synergies between radiation therapy and other treatment modalities, including their combined effects on tumor response and the immune system [6][8]. Finally, we will consider future directions in radiation therapy, focusing on personalized treatment approaches and the potential for novel radiosensitizers [11].

By synthesizing current research findings and clinical practices, this review aims to elucidate the complexities of radiation therapy in cancer treatment, providing insights that may inform future research and clinical strategies. Through a comprehensive understanding of radiation therapy's mechanisms, types, and technological advancements, we can better address the challenges posed by radioresistance and improve the overall effectiveness of cancer treatment.

2 Mechanisms of Radiation Therapy ​

2.1 Cellular Response to Radiation ​

Radiation therapy operates as a critical modality in cancer treatment, primarily through its capacity to induce cellular damage in cancerous tissues. The mechanisms underlying the cellular response to radiation involve a complex interplay of direct and indirect effects on tumor cells, ultimately leading to cell death or alterations in cellular behavior.

When cancer cells are exposed to ionizing radiation, the primary effect is the induction of DNA damage. This can manifest as single-strand breaks or double-strand breaks in the DNA helix, which are recognized and processed by cellular DNA damage response pathways. If the damage is extensive and irreparable, it can trigger programmed cell death pathways, such as apoptosis, necrosis, or senescence. The activation of these pathways is crucial as it determines the fate of the irradiated cells, leading to either cell death or survival and adaptation to the damage (Carlos-Reyes et al. 2021; Galeaz et al. 2021).

Interestingly, some tumor cells can exhibit radioresistance, which is an adaptive response characterized by enhanced DNA repair mechanisms and altered cellular processes that support tumor growth. For instance, ionizing radiation can activate various transcription factors, such as STAT3 and NF-κB, which promote the expression of anti-apoptotic genes and support cellular proliferation and survival (Galeaz et al. 2021). Moreover, the generation of reactive oxygen species (ROS) during radiation exposure can lead to cellular signaling changes that contribute to radioresistance by inducing antioxidant responses, thus diminishing the efficacy of radiation treatment (McCann et al. 2021).

In addition to direct effects on DNA, radiation also impacts subcellular structures and metabolic pathways within cancer cells. Mitochondria play a pivotal role in mediating the radiation response, as they are involved in energy production and apoptosis regulation. Changes in mitochondrial function can lead to alterations in cellular metabolism, further influencing the radioresistance of tumor cells (McCann et al. 2021).

The tumor microenvironment also significantly influences the response to radiation therapy. Radiation can modify the immune landscape by promoting immunogenic cell death, enhancing antigen presentation, and activating innate immune cells, such as macrophages. These immune responses can lead to either radiosensitization or radioresistance, depending on the specific tumor type and treatment regimen (Wu et al. 2017; Xuan et al. 2024). For example, radiation can program macrophages to adopt a pro-inflammatory phenotype, which can enhance the anti-tumor immune response and improve the efficacy of radiation therapy (Wu et al. 2017).

In summary, radiation therapy induces a multifaceted cellular response characterized by DNA damage, activation of cell death pathways, modulation of cellular metabolism, and alterations in the tumor microenvironment. Understanding these mechanisms is crucial for developing strategies to overcome radioresistance and improve therapeutic outcomes in cancer treatment (Carlos-Reyes et al. 2021; Galeaz et al. 2021; McCann et al. 2021).

2.2 DNA Damage and Repair Mechanisms ​

Radiation therapy (RT) is a critical modality in cancer treatment that leverages ionizing radiation to induce cellular damage in tumor cells. The primary mechanism by which RT exerts its therapeutic effects is through the generation of DNA damage, specifically DNA double-strand breaks (DSBs), which are considered the most lethal form of DNA damage induced by radiation. This damage triggers a complex cellular response involving DNA damage repair mechanisms, cell cycle regulation, and apoptosis.

Upon exposure to radiation, cancer cells can sustain various types of DNA damage, including single-strand breaks and DSBs, as well as indirect damage through the formation of free radicals that interact with cellular components, including the genome. The cellular response to such damage is initiated through the activation of the DNA damage response (DDR) pathways, which serve to detect the damage, halt the cell cycle, and activate repair processes to restore genomic integrity. If the damage is beyond repair, these pathways can also trigger programmed cell death mechanisms, such as apoptosis [3].

The effectiveness of RT is significantly influenced by the type and efficiency of the DNA repair mechanisms that the tumor cells employ. Two primary pathways for repairing DSBs are non-homologous end joining (NHEJ) and homologous recombination (HR). NHEJ is a quicker, error-prone repair process that can lead to mutations, while HR is a more accurate repair mechanism that relies on a homologous template. Tumor cells may exhibit variations in the functionality of these pathways, often leading to intrinsic or acquired radioresistance, which can hinder the effectiveness of radiation therapy [[pmid:20832019][12].

Research has shown that the cellular context, including the phase of the cell cycle, the microenvironment, and the levels of oxygenation, can significantly affect the choice of repair pathway. For instance, cells in the G2 phase of the cell cycle have a preference for HR when exposed to low doses of radiation, whereas high doses may push the repair process towards more error-prone mechanisms like NHEJ [12]. This differential engagement of repair pathways can contribute to the survival of tumor cells post-radiation exposure and their potential for recurrence [13].

Furthermore, the tumor microenvironment plays a crucial role in shaping the response to radiation. Factors such as hypoxia can enhance radioresistance by modulating the expression of genes involved in the DNA repair processes and apoptosis [3]. In addition, alterations in the expression of tumor suppressor genes and oncogenes in response to radiation can further influence the hallmarks of cancer, such as metastasis and invasion [3].

Overall, the interplay between DNA damage, repair mechanisms, and cellular responses to radiation is complex and multifaceted. Enhancing the efficacy of radiation therapy may involve targeting these DNA repair pathways to sensitize tumor cells to radiation-induced damage, thus improving treatment outcomes [[pmid:36521246][14]. Such strategies could lead to innovative therapeutic approaches that exploit the vulnerabilities of cancer cells in their response to DNA damage.

3 Types of Radiation Therapy ​

3.1 External Beam Radiation Therapy ​

External beam radiation therapy (EBRT) is a widely utilized treatment modality in modern cancer management, effective in both curative and palliative settings due to its safety and efficacy. The fundamental principle behind EBRT involves the use of high-energy radiation beams, such as X-rays or gamma rays, which are directed at cancerous tissues to induce DNA damage in malignant cells. This damage is primarily cytostatic and cytotoxic, ultimately leading to cell death. Notably, malignant cells typically exhibit a limited capacity for DNA repair compared to normal cells, which enhances the therapeutic efficacy of radiation therapy when combined with techniques that minimize collateral damage to surrounding healthy tissues[15].

EBRT has evolved significantly over the years, incorporating advancements in imaging and computer technology that improve targeting precision. This evolution has allowed for the delivery of higher doses of radiation directly to tumors while sparing adjacent normal tissues, thereby enhancing treatment outcomes. For instance, studies have shown that doses of 70 Gy delivered at 10 Gy per week have been safe and effective in treating localized prostate cancer, achieving 15-year survival rates ranging from 50% for less extensively localized tumors to 18% for more advanced cases[16].

In the context of specific cancers, such as prostate cancer, EBRT has been employed as a curative treatment for over five decades. The modern era of EBRT has seen significant improvements in techniques, leading to enhanced patient outcomes. Predictive factors influencing treatment efficacy and outcomes are crucial for tailoring individual patient management strategies[17]. Furthermore, combining EBRT with other treatment modalities, such as androgen deprivation therapy, has been explored to maximize therapeutic benefits[17].

While EBRT is effective, it is essential to recognize the potential risks associated with high-dose radiation delivery. Incorrect delivery can lead to severe complications in normal tissues and geographic misses can result in tumor recurrence[18]. As a result, continuous efforts are made to reduce treatment errors and ensure patient safety, emphasizing the importance of precise planning and execution in radiation therapy[18].

In summary, EBRT is a cornerstone of cancer treatment that leverages high-energy radiation to damage DNA in malignant cells, leading to their death. The treatment's effectiveness is enhanced by advancements in technology that improve targeting precision, although careful consideration of potential risks is paramount in optimizing patient outcomes.

3.2 Brachytherapy ​

Brachytherapy is a specialized form of radiation therapy that involves the precise placement of radioactive sources directly into or near a tumor. This technique is designed to deliver high doses of radiation to the tumor while minimizing exposure to surrounding healthy tissues, thereby reducing the likelihood of normal tissue complications. It is indicated for various types of cancers and is often used as a primary treatment or as part of a comprehensive oncologic care strategy.

The fundamental principle of brachytherapy lies in its ability to provide localized radiation treatment. By placing radioactive materials in close proximity to the tumor, brachytherapy achieves a high dose of radiation directly to the target area, which enhances the therapeutic ratio—meaning it maximizes tumor cell kill while sparing adjacent normal tissues. This is particularly beneficial in cases such as locally advanced cervical cancer, where brachytherapy is combined with chemoradiation, and in patients with high-risk prostate cancer, where it can help escalate doses and improve progression-free survival rates[19].

Brachytherapy can be categorized into two main types: intracavitary and interstitial. Intracavitary brachytherapy involves the placement of radioactive sources within body cavities, typically for a temporary duration of 1 to 4 days, while interstitial brachytherapy involves the implantation of radioactive seeds directly into the tumor tissue, which can be either temporary or permanent. Each method has distinct advantages depending on the specific clinical scenario and tumor characteristics[20].

The physical properties of the radioactive sources used in brachytherapy are crucial for treatment efficacy. Commonly used isotopes include cesium-137, iridium-192, iodine-125, and gold-198, each with varying half-lives and photon energies that influence their tissue penetration and dose distribution. Newer radionuclides such as americium-241, palladium-103, samarium-145, and ytterbium-169 have also been developed, offering a wider array of options for tailoring treatment to individual patient needs[20].

In recent years, advancements in imaging technologies, such as CT, MRI, and PET, have significantly improved the precision of brachytherapy. The incorporation of 3D image-guided procedures allows for more accurate treatment planning and delivery, leading to better clinical outcomes[21]. Furthermore, the increasing interest in focal and hypofractionated treatments highlights the potential for brachytherapy to evolve and adapt to new therapeutic indications[21].

Despite its benefits, the utilization of brachytherapy has seen a decline due to factors such as the complexity of the procedure, reimbursement challenges, and the need for high dexterity in its application. However, there is a growing recognition of its importance in oncology, with ongoing efforts to enhance its application and integration into cancer treatment protocols[22].

In summary, brachytherapy represents a critical modality in radiation oncology, providing targeted treatment options that optimize dose delivery to tumors while minimizing damage to surrounding healthy tissues. Its effectiveness, particularly in certain cancer types, underscores the importance of continued research and development in this field to improve patient outcomes and expand treatment possibilities.

3.3 Stereotactic Radiation Therapy ​

Radiation therapy is a pivotal modality in cancer treatment, leveraging high doses of ionizing radiation to target and eliminate cancer cells while shrinking tumors. It operates primarily by damaging the DNA within tumor cells, thereby inhibiting their proliferation. This treatment has been a cornerstone in oncology for over a century, used in conjunction with surgery and chemotherapy for various cancer types, including lung, breast, cervical, and colorectal cancers. Approximately 50% of cancer patients will require radiation therapy, with 60% of these treatments aimed at curative intent. However, it is also frequently employed for palliative care to alleviate symptoms such as pain and discomfort [1].

Among the various forms of radiation therapy, stereotactic radiation therapy (SRT) stands out as a novel and highly precise treatment approach. This technique delivers a small number of ultra-high doses of radiation to a defined target volume, utilizing advanced technology to achieve remarkable accuracy. Stereotactic body radiation therapy (SBRT), a subset of SRT, is particularly effective in treating early-stage cancers and oligometastatic disease, which refers to a limited number of metastatic tumors. SBRT has shown efficacy in treating cancers such as non-small-cell lung cancer, prostate cancer, renal-cell carcinoma, and liver cancer [23].

The advantages of SBRT include its ability to deliver high doses of radiation over a shorter period, typically within five days, while minimizing exposure to surrounding healthy tissues. This precision is critical in enhancing local control of tumors, particularly in patients who may not be candidates for surgery. Research indicates that SBRT can significantly improve disease control and palliation compared to conventional radiotherapy methods [24].

Furthermore, the integration of SBRT with immunotherapy has emerged as a promising strategy. Recent studies suggest that combining high-dose radiation with immune checkpoint inhibitors can enhance the therapeutic effect, leading to improved antitumor responses. The immunomodulatory effects of radiation are becoming increasingly recognized as vital contributors to treatment outcomes, with research focusing on understanding the underlying biological mechanisms [25].

In summary, radiation therapy, particularly in its stereotactic forms, plays a crucial role in the treatment of cancer by providing targeted and effective tumor control. The ongoing evolution of techniques and the exploration of combinatory approaches with immunotherapy continue to expand the potential of radiation therapy in improving patient outcomes.

4 Technological Advances in Radiation Therapy ​

4.1 Intensity-Modulated Radiation Therapy (IMRT) ​

Intensity-modulated radiation therapy (IMRT) is a sophisticated advancement in radiation oncology that significantly enhances the precision of radiation delivery to tumors while minimizing exposure to surrounding healthy tissues. This technique utilizes computer-controlled radiation deposition and inverse planning, allowing for a more conformal radiation dose distribution compared to conventional methods, which often relied on a trial-and-error approach [26].

IMRT employs multiple radiation beams, each modulated in intensity, to create a highly targeted radiation profile. This enables clinicians to deliver different doses to various parts of the tumor and simultaneously spare critical normal structures. The technique has been particularly beneficial in treating complex tumor shapes and locations, such as in the lungs and head and neck regions, where traditional two-dimensional or three-dimensional conformal radiotherapy might fail to adequately protect adjacent organs at risk (OARs) [[pmid:18778554],[pmid:28984841]].

The application of IMRT has been shown to reduce acute treatment-related morbidity, thereby making dose escalation feasible. This is particularly important as higher doses can lead to improved local tumor control. For instance, IMRT has been effectively utilized in the treatment of prostate cancer, where it has demonstrated a capacity to reduce both acute and late-occurring toxicities, enhancing the quality of life for patients [27].

In addition to its applications in prostate cancer, IMRT has also emerged as a promising option for treating cervical cancer. It has the potential to improve the therapeutic ratio by allowing for dose escalation to cancer targets while sparing adjacent healthy tissue, thus reducing the likelihood of adverse effects [[pmid:21147905],[pmid:37654111]]. Early studies have reported dosimetric benefits, including a reduction in gastrointestinal and hematologic toxicities in posthysterectomy patients treated with IMRT [28].

Furthermore, the technological evolution of IMRT continues to expand its utility across various cancer types. For instance, it is becoming increasingly recognized for its role in lung cancer management, where it improves dose conformity around the tumor while protecting normal structures, thereby enhancing treatment outcomes [29].

Overall, IMRT represents a paradigm shift in radiation therapy, allowing for tailored treatment strategies that not only target tumors effectively but also prioritize patient safety and quality of life. As research continues to evolve, the integration of IMRT with other modalities, such as immunotherapy, may further enhance its efficacy in cancer treatment [30].

4.2 Image-Guided Radiation Therapy (IGRT) ​

Radiation therapy is a pivotal modality in cancer treatment, characterized by its ability to target and destroy malignant cells through the application of ionizing radiation. Recent advancements, particularly in the realm of image-guided radiation therapy (IGRT), have significantly enhanced the precision and efficacy of this treatment approach.

IGRT represents a technological evolution that integrates imaging techniques into the radiotherapy process, enabling real-time localization of tumors and surrounding tissues. This advancement is crucial as it allows clinicians to adjust treatment plans dynamically, accommodating changes in tumor size and position throughout the course of therapy. The fundamental goal of IGRT is to maximize the radiation dose delivered to the tumor while minimizing exposure to adjacent healthy tissues, thereby reducing potential side effects and improving patient outcomes.

The implementation of IGRT involves various imaging modalities, such as computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound, which can be utilized at different stages of treatment. For instance, on-board imaging (OBI) systems are often employed in conjunction with linear accelerators to facilitate precise tumor localization. This integration allows for the detection of inter- and intrafractional variations, which can occur due to factors like patient movement, organ filling changes, or tumor shrinkage. By correcting for these variations, IGRT enhances the accuracy of radiation delivery, thus increasing the likelihood of effective tumor control while sparing normal tissues from unnecessary radiation exposure [31][32][33].

Moreover, IGRT is instrumental in the planning phase of radiation therapy. During treatment planning, imaging data is utilized to delineate target volumes and critical structures, ensuring that the radiation dose distribution is optimized. The ability to visualize the tumor and surrounding anatomy in real-time allows for meticulous adjustments to the treatment plan, which is vital for achieving high-quality, safe radiation therapy [34][35].

Clinical studies have demonstrated that the adoption of IGRT can lead to improved dosimetric outcomes and enhanced clinical results. For example, in prostate cancer treatment, IGRT has been shown to improve the accuracy of dose delivery, leading to better treatment outcomes and fewer complications associated with radiation exposure to organs at risk, such as the bladder and rectum [33][36]. Furthermore, the precise targeting capabilities of IGRT enable the application of high-precision techniques, such as volumetric modulated arc therapy, which can further optimize treatment plans [37].

In conclusion, the technological advancements represented by IGRT have revolutionized radiation therapy, providing clinicians with the tools necessary to deliver more accurate and effective cancer treatments. By integrating sophisticated imaging techniques into the treatment process, IGRT enhances the safety and efficacy of radiation therapy, paving the way for personalized treatment approaches that cater to the unique anatomical and pathological characteristics of each patient’s cancer.

4.3 Proton Therapy ​

Proton therapy is an innovative approach in cancer treatment that utilizes protons, charged particles, to deliver radiation to tumors. This modality offers distinct advantages over conventional photon-based radiotherapy, primarily due to its ability to precisely target tumor volumes while minimizing radiation exposure to surrounding healthy tissues. The mechanism of action of proton therapy is rooted in the unique physical properties of protons, which deposit energy in a controlled manner, resulting in a sharp dose distribution.

Protons have a finite range in tissue, which means they can be tuned to release their maximum energy directly within the tumor, known as the Bragg peak. This characteristic allows for significant dose escalation to the tumor while reducing the radiation dose to adjacent normal tissues, thereby decreasing the likelihood of side effects and long-term complications, such as secondary cancers. For instance, in pediatric patients, where the risk of radiation-induced secondary malignancies is a critical concern, proton therapy can significantly spare healthy tissues compared to conventional techniques [38].

The clinical effectiveness of proton therapy has been evaluated through various studies. A systematic review included 54 publications, comprising randomized controlled trials (RCTs), comparative studies, and case series. Some studies indicated that proton therapy could improve biochemical local control in prostate cancer without increasing serious complication rates. However, the evidence largely stems from non-controlled studies, which suggests a need for further rigorous research to establish definitive clinical efficacy [39].

Recent advancements in the integration of gold nanoparticles with proton therapy have emerged as a promising strategy to enhance treatment outcomes. Gold nanoparticles serve as radiosensitizers, amplifying the effects of proton irradiation by increasing the generation of secondary electrons and reactive oxygen species, which in turn leads to enhanced DNA damage in tumor cells while preserving healthy tissues [40]. This synergy between proton therapy and nanotechnology may improve therapeutic precision and efficacy across a broader spectrum of cancers.

In specific applications, proton therapy has shown effectiveness in treating various malignancies, including pediatric tumors like medulloblastoma and Ewing's sarcoma, as well as adult cancers such as hepatocellular carcinoma and pancreatic cancer. The dosimetric advantages of proton therapy allow for better conformity to tumor shapes and the potential for higher radiation doses to be safely administered [41], [42].

Despite its benefits, proton therapy is not without challenges. Considerations such as the finite range of protons, temporal effects, and the choice between different proton delivery systems (passive scattering vs. active scanning) are crucial for optimizing treatment plans [43]. As research progresses, the goal is to refine these techniques and enhance the accessibility of proton therapy for patients worldwide.

In summary, proton therapy represents a significant advancement in radiation oncology, offering a targeted and effective treatment option for various cancers. Its ability to minimize damage to healthy tissues while maximizing tumor control underscores its potential as a cornerstone in modern cancer treatment paradigms.

5 Combination with Other Treatment Modalities ​

5.1 Radiation Therapy and Chemotherapy ​

Radiation therapy is a cornerstone in the management of cancer, utilized primarily to eliminate cancer cells and shrink tumors through the application of high doses of ionizing radiation. This treatment modality works by damaging the DNA within tumor cells, which inhibits their ability to proliferate and ultimately leads to cell death. It is commonly employed as a definitive local treatment for inoperable locoregionally confined tumors and as palliative therapy for symptomatic relief in advanced disease stages. Approximately 60% of cancer patients receive radiation therapy at some point during their treatment, highlighting its widespread use and significance in oncology [44].

The effectiveness of radiation therapy can be enhanced when used in conjunction with other treatment modalities, particularly chemotherapy. Chemotherapy, which employs cytotoxic agents to kill rapidly dividing cells, has been shown to improve local tumor control when combined with radiation therapy. However, the benefits of this combination are often modest, and there is a recognized need for further enhancement of treatment efficacy beyond what is achievable through sequential or concurrent administration of chemotherapy alone [44].

In recent years, the combination of radiation therapy with immunotherapy has gained traction as a promising strategy to augment treatment outcomes. Radiation not only directly induces DNA damage in tumor cells but also has the potential to modulate the immune microenvironment, transforming "cold" tumors into "hot" tumors that are more responsive to immunotherapeutic agents. This synergy can activate systemic anti-tumor immune responses, leading to improved patient survival and quality of life [45].

Despite the potential benefits, challenges remain in optimizing the timing, sequencing, and dosing of radiation therapy when combined with chemotherapy or immunotherapy. Preclinical studies have shown that various biological pathways can enhance the effectiveness of radiation therapy, but translating these findings into clinical practice has been hindered by a lack of standardized experimental models and evidence [44]. Ongoing research is focused on identifying specific biomarkers of radioresistance, which can help tailor treatments to improve outcomes for patients [1].

In conclusion, radiation therapy serves as a vital component of cancer treatment, with its efficacy significantly enhanced when combined with other modalities such as chemotherapy and immunotherapy. Continued exploration of the mechanisms underlying these combinations is essential to optimize treatment strategies and ultimately improve patient outcomes in cancer care.

5.2 Radiation Therapy and Immunotherapy ​

Radiation therapy (RT) is a pivotal component in cancer treatment, functioning primarily through the induction of DNA damage in tumor cells via ionizing radiation. This damage leads to direct cell death or growth arrest, thereby targeting cancer cells effectively. However, the role of radiation therapy extends beyond mere cytotoxicity; it also significantly influences the immune response against tumors, particularly when combined with immunotherapy.

Immunotherapy works by harnessing and enhancing the body’s immune system to recognize and destroy cancer cells. The combination of RT with immunotherapy has garnered attention due to its potential to synergistically improve treatment outcomes. The mechanisms underlying this synergy are multifaceted. For instance, radiation can induce the release of tumor-associated antigens and pro-inflammatory cytokines, which enhance the immunogenicity of the tumor microenvironment. This, in turn, can stimulate dendritic cells to present these antigens more effectively to T cells, thus activating a robust adaptive immune response [45][46].

The interplay between RT and immunotherapy is particularly notable in the transformation of the tumor microenvironment. Radiation can convert "cold" tumors, which are typically non-immunogenic and resistant to immune attacks, into "hot" tumors that elicit a strong immune response. This transformation is crucial as it allows immunotherapeutic agents, such as immune checkpoint inhibitors, to exert their effects more effectively [45].

Research indicates that the timing and sequencing of RT and immunotherapy are critical factors influencing their combined efficacy. Adjusting the radiation dose and timing can optimize the therapeutic window, maximizing the immune response while minimizing potential adverse effects. For example, studies have shown that certain dose adjustments can enhance antitumor immunity and improve disease prognosis compared to monotherapy approaches [46].

Moreover, the combination of RT with immunotherapeutic agents has demonstrated effectiveness in various cancers, including non-small cell lung cancer and melanoma. The synergistic effect of these modalities has been linked to enhanced local tumor control and improved systemic immune responses, which are vital for combating metastases [45].

In summary, radiation therapy operates not only by directly damaging cancer cells but also by modulating the immune landscape, enhancing the effectiveness of subsequent immunotherapy. This combination approach is an evolving area of research, with ongoing studies focused on optimizing treatment protocols to improve clinical outcomes for cancer patients.

6 Future Directions in Radiation Therapy ​

6.1 Personalized Radiation Therapy ​

Radiation therapy, or radiotherapy, is a medical treatment that utilizes high doses of ionizing radiation to eliminate cancer cells and reduce tumor size. This treatment modality has been employed for over a century and is now a standard approach for various cancers, including lung, breast, cervical, and colorectal cancers. Approximately 50% of all cancer patients will require radiotherapy at some point, with 60% of these treatments aimed at curative intent. Additionally, radiotherapy is frequently utilized for palliative care to alleviate symptoms associated with advanced cancer stages [1].

The fundamental mechanism of radiation therapy involves targeting the DNA within tumor cells. By inducing DNA damage, particularly double-strand breaks, radiation restricts the proliferation of cancer cells. The effectiveness of radiotherapy can be influenced by several factors, including the type of radiation used, the total dose administered, the number of treatment fractions, and the inherent radiosensitivity of the targeted cells [6]. Despite its effectiveness, a significant challenge in radiotherapy is the development of radiation resistance, which can lead to cancer recurrence and metastasis [1].

Future directions in radiation therapy focus on enhancing its efficacy and minimizing side effects through personalized approaches. Personalized radiation therapy aims to tailor treatment plans based on the individual characteristics of the tumor and the patient. This includes the identification of radioresistance biomarkers, which are proteins involved in metabolism and cell signaling pathways that can help predict treatment outcomes [1]. Advances in technology, such as image-guided radiotherapy and particle therapies, are also being explored to improve treatment quality and efficacy while sparing healthy tissues [4].

Furthermore, the integration of radiation therapy with immunotherapy represents a promising avenue for enhancing treatment outcomes. The combination of these modalities can potentially activate systemic anti-tumor immune responses, transforming "cold" tumors into "hot" tumors that are more responsive to treatment [45]. Ongoing research aims to optimize the timing and sequencing of radiation therapy with immunotherapy to maximize therapeutic benefits [8].

Overall, the future of radiation therapy lies in its ability to adapt to individual patient needs and the evolving understanding of cancer biology, which will facilitate more effective and targeted treatment strategies. Continued investigation into the biological mechanisms underlying radiation response and resistance will be crucial for improving therapeutic efficacy and patient outcomes in cancer care.

6.2 Research on Radio-sensitizers ​

Radiation therapy (RT) is a pivotal treatment modality in oncology, employed in the management of various malignancies. The primary mechanism of action involves the utilization of high doses of ionizing radiation to induce cytotoxic effects in cancer cells. This is achieved through two main pathways: generating reactive oxygen species (ROS) that damage DNA and directly causing DNA strand breaks. However, a significant challenge in the effectiveness of RT is the inherent radioresistance exhibited by many tumor cells, which can lead to treatment failure.

Recent advancements in the field have highlighted the role of radiosensitizers—agents that enhance the sensitivity of tumor cells to radiation. These can be categorized into several types, including small molecules, macromolecules, and nanoparticles. The incorporation of radiosensitizers aims to amplify the effects of radiation by increasing DNA damage and promoting the production of free radicals specifically within the tumor microenvironment, thereby enhancing the overall efficacy of RT while minimizing damage to surrounding healthy tissues[47][48].

Research has demonstrated various strategies to develop effective radiosensitizers. For instance, nanoparticles, particularly those with high atomic numbers (high-Z nanoparticles), have gained attention due to their unique properties that enhance radiation dose deposition in tumors. These nanoparticles can produce significant amounts of secondary electrons upon irradiation, leading to increased ROS generation and subsequent tumor cell death[49][50]. Furthermore, the development of multifunctional nanoparticles has shown promise in clinical applications, allowing for targeted delivery of therapeutic agents directly to cancer cells, which can further mitigate radioresistance[48].

In the context of future directions in radiation therapy, the integration of nanotechnology and the development of novel radiosensitizers are at the forefront of research. Ongoing studies are focusing on elucidating the underlying biological mechanisms that govern radiosensitization, such as the modulation of oxidative stress, DNA damage response, and cell cycle regulation. Additionally, the potential of natural compounds, such as resveratrol and curcumin, as radiosensitizers is being explored, providing a complementary approach to enhance the effects of conventional RT[51][52].

The challenges that remain include overcoming the complexity of tumor biology, addressing the variability in patient responses to treatment, and ensuring the safety and efficacy of new agents in clinical settings. Continued exploration of biomarkers for predicting radiosensitivity and the implementation of personalized treatment strategies are critical for advancing the field of radiation oncology[48][53].

In conclusion, radiation therapy remains a cornerstone in cancer treatment, and the future of this modality lies in the strategic application of radiosensitizers and innovative nanotechnology to enhance therapeutic outcomes while minimizing adverse effects.

7 Conclusion ​

The review of radiation therapy in cancer treatment highlights several key findings. Firstly, radiation therapy effectively induces cellular damage in cancer cells primarily through DNA damage, which can lead to cell death or radioresistance depending on the tumor's biological characteristics. Understanding the mechanisms of cellular response, including DNA repair pathways and the influence of the tumor microenvironment, is essential for developing strategies to enhance radiosensitivity and combat radioresistance. Secondly, advancements in radiation therapy techniques, such as external beam radiation therapy, brachytherapy, stereotactic radiation therapy, intensity-modulated radiation therapy, image-guided radiation therapy, and proton therapy, have significantly improved the precision and effectiveness of treatment while minimizing collateral damage to healthy tissues. Additionally, the integration of radiation therapy with other modalities, particularly chemotherapy and immunotherapy, has shown promise in improving patient outcomes through synergistic effects. Future research should focus on personalized radiation therapy approaches, the identification of radiosensitizers, and the incorporation of novel technologies to enhance treatment efficacy and reduce side effects. Overall, a multidisciplinary approach that combines these advancements will be critical in addressing the challenges posed by cancer treatment and improving the quality of care for patients.

References ​

  • [1] Almaz A Akhunzianov;Elvira V Rozhina;Yuliya V Filina;Albert A Rizvanov;Regina R Miftakhova. Resistance to Radiotherapy in Cancer.. Diseases (Basel, Switzerland)(IF=3.0). 2025. PMID:39851486. DOI: 10.3390/diseases13010022.
  • [2] Chiara Galeaz;Cristina Totis;Alessandra Bisio. Radiation Resistance: A Matter of Transcription Factors.. Frontiers in oncology(IF=3.3). 2021. PMID:34141616. DOI: 10.3389/fonc.2021.662840.
  • [3] Angeles Carlos-Reyes;Marcos A Muñiz-Lino;Susana Romero-Garcia;César López-Camarillo;Olga N Hernández-de la Cruz. Biological Adaptations of Tumor Cells to Radiation Therapy.. Frontiers in oncology(IF=3.3). 2021. PMID:34900673. DOI: 10.3389/fonc.2021.718636.
  • [4] Samuel Valable;Mathieu Césaire;Kilian Lecrosnier;Antoine Gilbert;Mihaela Tudor;Guillaume Vares;Dounia Houria Hamdi;Ousseynou Ben Diouf;Thao Nguyen Pham;Julie Coupey;Juliette Thariat;Paul Lesueur;Elodie Anne Pérès;Juliette Aury-Landas;Zacharenia Nikitaki;Siamak Haghdoost;Carine Laurent;Jean-Christophe Poully;Jacques Balosso;Myriam Bernaudin;Diana I Savu;François Chevalier. Particle Therapy to Overcome Cancer Radiation Resistance: "ARCHADE" Consortium Updates in Radiation Biology.. Cancers(IF=4.4). 2025. PMID:40361506. DOI: 10.3390/cancers17091580.
  • [5] Qiuji Wu;Awatef Allouch;Isabelle Martins;Nazanine Modjtahedi;Eric Deutsch;Jean-Luc Perfettini. Macrophage biology plays a central role during ionizing radiation-elicited tumor response.. Biomedical journal(IF=4.4). 2017. PMID:28918908. DOI: 10.1016/j.bj.2017.06.003.
  • [6] Byron Burnette;Ralph R Weichselbaum. Radiation as an immune modulator.. Seminars in radiation oncology(IF=3.2). 2013. PMID:24012341. DOI: .
  • [7] Wanyeon Kim;Sungmin Lee;Danbi Seo;Dain Kim;Kyeongmin Kim;EunGi Kim;JiHoon Kang;Ki Moon Seong;HyeSook Youn;BuHyun Youn. Cellular Stress Responses in Radiotherapy.. Cells(IF=5.2). 2019. PMID:31540530. DOI: 10.3390/cells8091105.
  • [8] Lihui Xuan;Chenjun Bai;Zhao Ju;Jinhua Luo;Hua Guan;Ping-Kun Zhou;Ruixue Huang. Radiation-targeted immunotherapy: A new perspective in cancer radiotherapy.. Cytokine & growth factor reviews(IF=11.8). 2024. PMID:38061920. DOI: 10.1016/j.cytogfr.2023.11.003.
  • [9] Mohammad Varzandeh;Sheyda Labbaf;Jaleh Varshosaz;Sophie Laurent. An overview of the intracellular localization of high-Z nanoradiosensitizers.. Progress in biophysics and molecular biology(IF=4.5). 2022. PMID:36029849. DOI: 10.1016/j.pbiomolbio.2022.08.006.
  • [10] Sharda Kumari;Shibani Mukherjee;Debapriya Sinha;Salim Abdisalaam;Sunil Krishnan;Aroumougame Asaithamby. Immunomodulatory Effects of Radiotherapy.. International journal of molecular sciences(IF=4.9). 2020. PMID:33142765. DOI: 10.3390/ijms21218151.
  • [11] Deyao Zhao;Yingyi Mo;Margarita E Neganova;Yulia Aleksandrova;Edmund Tse;Vladimir N Chubarev;Ruitai Fan;Olga A Sukocheva;Junqi Liu. Dual effects of radiotherapy on tumor microenvironment and its contribution towards the development of resistance to immunotherapy in gastrointestinal and thoracic cancers.. Frontiers in cell and developmental biology(IF=4.3). 2023. PMID:37849740. DOI: 10.3389/fcell.2023.1266537.
  • [12] Emil Mladenov;Veronika Mladenova;Martin Stuschke;George Iliakis. New Facets of DNA Double Strand Break Repair: Radiation Dose as Key Determinant of HR versus c-NHEJ Engagement.. International journal of molecular sciences(IF=4.9). 2023. PMID:37834403. DOI: 10.3390/ijms241914956.
  • [13] Antonella Porrazzo;Matteo Cassandri;Andrea D'Alessandro;Patrizia Morciano;Rossella Rota;Francesco Marampon;Giovanni Cenci. DNA repair in tumor radioresistance: insights from fruit flies genetics.. Cellular oncology (Dordrecht, Netherlands)(IF=4.8). 2024. PMID:38095764. DOI: 10.1007/s13402-023-00906-6.
  • [14] Julian Biau;Emmanuel Chautard;Pierre Verrelle;Marie Dutreix. Altering DNA Repair to Improve Radiation Therapy: Specific and Multiple Pathway Targeting.. Frontiers in oncology(IF=3.3). 2019. PMID:31649878. DOI: 10.3389/fonc.2019.01009.
  • [15] Emma Guilbaud;Flavie Naulin;Lydia Meziani;Eric Deutsch;Lorenzo Galluzzi. Impact of radiation therapy on the immunological tumor microenvironment.. Cell chemical biology(IF=7.2). 2025. PMID:40280118. DOI: 10.1016/j.chembiol.2025.04.001.
  • [16] M A Bagshaw;I D Kaplan;R C Cox. Prostate cancer. Radiation therapy for localized disease.. Cancer(IF=5.1). 1993. PMID:8428344. DOI: 10.1002/1097-0142(19930201)71:3+<939::aid-cncr2820711409>3.0.co;2-0.
  • [17] Thomas M Pisansky. External beam radiotherapy as curative treatment of prostate cancer.. Mayo Clinic proceedings(IF=6.7). 2005. PMID:16007894. DOI: 10.4065/80.7.883.
  • [18] Ellen Yorke;Daphna Gelblum;Eric Ford. Patient safety in external beam radiation therapy.. AJR. American journal of roentgenology(IF=6.1). 2011. PMID:21427323. DOI: 10.2214/AJR.10.6006.
  • [19] Cyrus Chargari;Eric Deutsch;Pierre Blanchard;Sebastien Gouy;Hélène Martelli;Florent Guérin;Isabelle Dumas;Alberto Bossi;Philippe Morice;Akila N Viswanathan;Christine Haie-Meder. Brachytherapy: An overview for clinicians.. CA: a cancer journal for clinicians(IF=232.4). 2019. PMID:31361333. DOI: 10.3322/caac.21578.
  • [20] Nath. New Directions in Radionuclide Sources for Brachytherapy.. Seminars in radiation oncology(IF=3.2). 1993. PMID:10717080. DOI: 10.1053/SRAO00300278.
  • [21] Kari Tanderup;Cynthia Ménard;Csaba Polgar;Jacob Christian Lindegaard;Christian Kirisits;Richard Pötter. Advancements in brachytherapy.. Advanced drug delivery reviews(IF=17.6). 2017. PMID:27637454. DOI: 10.1016/j.addr.2016.09.002.
  • [22] William Y Song;Michael Roumeliotis;Junghoon Lee;Aaron Fenster;Jessica Rodgers;Tiana Trumpour;Rachel M Glicksman;Alejandro Berlin;Åsa Carlsson Tedgren;Javier Vijande;Luc Beaulieu;Björn Morén;Sandra Meyers;Alexandra Rink;Yin Gao;Benjamin P Fahimian;Debarghya China;Kai Ding;Tarun K Podder;Eric N Carver;Mark J Rivard;Susan Richardson;Milan Grkovski;Moeen Meftahi;Ulysses Gardner;Rachit Kumar;Daniel Scanderbeg;Catheryn Yashar;Issam El Naqa;Akila N Viswanathan;Xun Jia. Roadmap: medical physics technologies in brachytherapy.. Physics in medicine and biology(IF=3.4). 2025. PMID:40480262. DOI: 10.1088/1361-6560/ade21f.
  • [23] Simon S Lo;Achilles J Fakiris;Eric L Chang;Nina A Mayr;Jian Z Wang;Lech Papiez;Bin S Teh;Ronald C McGarry;Higinia R Cardenes;Robert D Timmerman. Stereotactic body radiation therapy: a novel treatment modality.. Nature reviews. Clinical oncology(IF=82.2). 2010. PMID:19997074. DOI: 10.1038/nrclinonc.2009.188.
  • [24] Joseph K Salama;John P Kirkpatrick;Fang-Fang Yin. Stereotactic body radiotherapy treatment of extracranial metastases.. Nature reviews. Clinical oncology(IF=82.2). 2012. PMID:23007273. DOI: 10.1038/nrclinonc.2012.166.
  • [25] David Friedman;Jason R Baird;Kristina H Young;Benjamin Cottam;Marka R Crittenden;Scott Friedman;Michael J Gough;Pippa Newell. Programmed cell death-1 blockade enhances response to stereotactic radiation in an orthotopic murine model of hepatocellular carcinoma.. Hepatology research : the official journal of the Japan Society of Hepatology(IF=3.4). 2017. PMID:27501850. DOI: 10.1111/hepr.12789.
  • [26] B S Teh;S Y Woo;E B Butler. Intensity modulated radiation therapy (IMRT): a new promising technology in radiation oncology.. The oncologist(IF=4.2). 1999. PMID:10631687. DOI: .
  • [27] Michael J Zelefsky;Zvi Fuks;Steven A Leibel. Intensity-modulated radiation therapy for prostate cancer.. Seminars in radiation oncology(IF=3.2). 2002. PMID:12118388. DOI: 10.1053/srao.2002.00000.
  • [28] Christopher Loiselle;Wui-Jin Koh. The emerging use of IMRT for treatment of cervical cancer.. Journal of the National Comprehensive Cancer Network : JNCCN(IF=16.4). 2010. PMID:21147905. DOI: 10.6004/jnccn.2010.0106.
  • [29] Clara Chan;Stephanie Lang;Carl Rowbottom;Matthias Guckenberger;Corinne Faivre-Finn; . Intensity-modulated radiotherapy for lung cancer: current status and future developments.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer(IF=20.8). 2014. PMID:25436795. DOI: 10.1097/JTO.0000000000000346.
  • [30] Radhe Mohan. Intensity-modulated radiation therapy - you can have your cake and eat it too!. Medical physics(IF=3.2). 2023. PMID:36377546. DOI: 10.1002/mp.16100.
  • [31] David A Jaffray;Katja M Langen;Gikas Mageras;Laura A Dawson;Di Yan;Robert Adams EdD;Arno J Mundt;Benedick Fraass. Safety considerations for IGRT: Executive summary.. Practical radiation oncology(IF=3.5). 2013. PMID:24175003. DOI: 10.1016/j.prro.2013.01.004.
  • [32] Dirk Verellen;Mark De Ridder;Guy Storme. A (short) history of image-guided radiotherapy.. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology(IF=5.3). 2008. PMID:18083259. DOI: 10.1016/j.radonc.2007.11.023.
  • [33] Florentina Larisa Coc;Loredana G Marcu. From CBCT to MR-Linac in Image-Guided Prostate Cancer Radiotherapy Towards Treatment Personalization.. Current oncology (Toronto, Ont.)(IF=3.4). 2025. PMID:40558234. DOI: 10.3390/curroncol32060291.
  • [34] Laura A Dawson;David A Jaffray. Advances in image-guided radiation therapy.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology(IF=41.9). 2007. PMID:17350942. DOI: 10.1200/JCO.2006.09.9515.
  • [35] Anil Sethi;Dimitris N Mihailidis. On-Treatment Verification Imaging.. Medical physics(IF=3.2). 2020. PMID:33382461. DOI: 10.1002/mp.14693.
  • [36] Hsin-Hua Nien;Li-Ying Wang;Li-Jen Liao;Ping-Yi Lin;Chia-Yun Wu;Pei-Wei Shueng;Chen-Shuan Chung;Wu-Chia Lo;Shih-Chiang Lin;Chen-Hsi Hsieh. Advances in Image-Guided Radiotherapy in the Treatment of Oral Cavity Cancer.. Cancers(IF=4.4). 2022. PMID:36230553. DOI: 10.3390/cancers14194630.
  • [37] Vincent Grégoire;Matthias Guckenberger;Karin Haustermans;Jan J W Lagendijk;Cynthia Ménard;Richard Pötter;Ben J Slotman;Kari Tanderup;Daniela Thorwarth;Marcel van Herk;Daniel Zips. Image guidance in radiation therapy for better cure of cancer.. Molecular oncology(IF=4.5). 2020. PMID:32536001. DOI: 10.1002/1878-0261.12751.
  • [38] Barbara Rombi;Sabina Vennarini;Lorenzo Vinante;Daniele Ravanelli;Maurizio Amichetti. Proton radiotherapy for pediatric tumors: review of first clinical results.. Italian journal of pediatrics(IF=3.1). 2014. PMID:25260976. DOI: 10.1186/s13052-014-0074-6.
  • [39] Dag Rune Olsen;Oyvind S Bruland;Gunilla Frykholm;Inger Natvig Norderhaug. Proton therapy - a systematic review of clinical effectiveness.. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology(IF=5.3). 2007. PMID:17499374. DOI: 10.1016/j.radonc.2007.03.001.
  • [40] Giorgio Giuseppe Carbone;Stefania Mariano;Alessandra Gabriele;Sabrina Cennamo;Vitantonio Primiceri;Muhammad Rizwan Aziz;Elisa Panzarini;Lucio Calcagnile. Exploring the Potential of Gold Nanoparticles in Proton Therapy: Mechanisms, Advances, and Clinical Horizons.. Pharmaceutics(IF=5.5). 2025. PMID:40006543. DOI: 10.3390/pharmaceutics17020176.
  • [41] Ann Raldow;James Lamb;Theodore Hong. Proton beam therapy for tumors of the upper abdomen.. The British journal of radiology(IF=3.4). 2020. PMID:31430202. DOI: 10.1259/bjr.20190226.
  • [42] Cristina Müller;Maria De Prado Leal;Marco D Dominietto;Christoph A Umbricht;Sairos Safai;Rosalind L Perrin;Martina Egloff;Peter Bernhardt;Nicholas P van der Meulen;Damien C Weber;Roger Schibli;Antony J Lomax. Combination of Proton Therapy and Radionuclide Therapy in Mice: Preclinical Pilot Study at the Paul Scherrer Institute.. Pharmaceutics(IF=5.5). 2019. PMID:31480730. DOI: 10.3390/pharmaceutics11090450.
  • [43] Sara St James;Clemens Grassberger;Hsiao-Ming Lu. Considerations when treating lung cancer with passive scatter or active scanning proton therapy.. Translational lung cancer research(IF=3.5). 2018. PMID:29876321. DOI: 10.21037/tlcr.2018.04.01.
  • [44] Steven H Lin;Henning Willers;Sunil Krishnan;Jann N Sarkaria;Michael Baumann;Theodore S Lawrence. Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations.. International journal of radiation oncology, biology, physics(IF=6.5). 2021. PMID:34454045. DOI: 10.1016/j.ijrobp.2021.08.018.
  • [45] JingLong Jiang;HouZe Li;QingCui Ma;Jing Liu;Fu Ren;YingQiu Song;TianLu Wang;KeYan Li;Ning Li. Synergies between radiotherapy and immunotherapy: a systematic review from mechanism to clinical application.. Frontiers in immunology(IF=5.9). 2025. PMID:40861450. DOI: 10.3389/fimmu.2025.1554499.
  • [46] Xuewei Li;Chen Wang;Haiou Yang;Wenhui Xue;Yaqian Ding;Na Wu;Beibei Pei;Xiaoyan Ma;Wenhui Yang. Immunotherapy and radiotherapy: An effective combination in cancer treatment.. Chinese medical journal(IF=7.3). 2025. PMID:40764050. DOI: 10.1097/CM9.0000000000003609.
  • [47] Liuyun Gong;Yujie Zhang;Chengcheng Liu;Mingzhen Zhang;Suxia Han. Application of Radiosensitizers in Cancer Radiotherapy.. International journal of nanomedicine(IF=6.5). 2021. PMID:33603370. DOI: 10.2147/IJN.S290438.
  • [48] Xiaoyu Song;Zhenkun Sun;Li Li;Lu Zhou;Shuanghu Yuan. Application of nanomedicine in radiotherapy sensitization.. Frontiers in oncology(IF=3.3). 2023. PMID:36874097. DOI: 10.3389/fonc.2023.1088878.
  • [49] Hongxin Shen;Hong Huang;Zhimei Jiang. Nanoparticle-based radiosensitization strategies for improving radiation therapy.. Frontiers in pharmacology(IF=4.8). 2023. PMID:36873996. DOI: 10.3389/fphar.2023.1145551.
  • [50] Ya Wang;Huilin Zhang;Yanyan Liu;Muhsin H Younis;Weibo Cai;Wenbo Bu. Catalytic radiosensitization: Insights from materials physicochemistry.. Materials today (Kidlington, England)(IF=22.0). 2022. PMID:36425004. DOI: 10.1016/j.mattod.2022.05.022.
  • [51] Dominika Komorowska;Tomasz Radzik;Sebastian Kalenik;Aleksandra Rodacka. Natural Radiosensitizers in Radiotherapy: Cancer Treatment by Combining Ionizing Radiation with Resveratrol.. International journal of molecular sciences(IF=4.9). 2022. PMID:36142554. DOI: 10.3390/ijms231810627.
  • [52] Yuanyuan Zhao;Fangqin Tan;Jiajia Zhao;Shuchang Zhou;Yao Luo;Chen Gong. Targeting the Enhanced Sensitivity of Radiotherapy in Cancer: Mechanisms, Applications, and Challenges.. MedComm(IF=10.7). 2025. PMID:40384989. DOI: 10.1002/mco2.70202.
  • [53] Fatemeh Shiridokht;Parniya Kehtari;Morteza Eskandani;Alireza Farajollahi;Somayeh Vandghanooni. Advancing cancer radiotherapy: Harnessing radiosensitizers and nanotechnology for enhanced tumor control.. International journal of pharmaceutics: X(IF=6.4). 2025. PMID:41189671. DOI: 10.1016/j.ijpx.2025.100419.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Radiation Therapy · Cancer · DNA Damage · Radioresistance · Personalized Treatment

© 2025 MaltSci